Can high-dose interleukin-2 be replaced with lower-dose, outpatient regimens for metastatic renal cell carcinoma?

Christopher G. Wood

Research output: Contribution to journal › Short survey › peer-review

Fingerprint

Dive into the research topics of 'Can high-dose interleukin-2 be replaced with lower-dose, outpatient regimens for metastatic renal cell carcinoma?'. Together they form a unique fingerprint.